EGFR MUTATION STATUS ON BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 96; pp. 101 - 107
• Main Authors: Hsu, Fred, De Caluwe, Alex, Anderson, David, Nichol, Alan, Toriumi, Ted, Ho, Cheryl
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.06.2016
• Subjects: Adult; Aged; Aged, 80 and over; Brain metastases; Brain Neoplasms - enzymology; Brain Neoplasms - genetics; Brain Neoplasms - secondary; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Disease-Free Survival; EGFR; Female; Hematology, Oncology and Palliative Medicine; Humans; Incidence; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors - therapeutic use; Pulmonary/Respiratory; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Retrospective Studies; TKI; lung cancer; TKI; chemotherapy; brain metastases; EGFR; Chemotherapy; Brain metastases; Lung cancer
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2016.04.004

Highlights • A higher incidence of brain metastases with EGFR mutation positive lung cancer. • Age and EGFR mutation status are risk factors for developing brain metastases. • Systemic therapy does not impact the incidence of brain metastases. • Most brain metastases are detected within the first year of metastatic diagnosis. • Brain metastases are an independent negative prognostic factor.